Skip to search formSkip to main contentSkip to account menu

alefacept

Known as: alefacept [Chemical/Ingredient], LFA3TIP, LFA-3 IgG(1) fusion protein 
A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3… 
National Institutes of Health

Related topics

Related topics

9 relations
CD2 AntigensCytotoxic T-LymphocytesDrug AllergyImmunoconjugates

Broader (2)

Dermatologic AgentsRecombinant Fusion Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Alefacept treatment for refractory chronic extensive GVHD
Alefacept (Amevive) is an immunosuppressive dimeric fusion protein that is used for psoriasis control. We recently showed its… 
Review
2006
Review
2006
Long-term management of plaque psoriasis with continuous efalizumab therapy.
2005
2005
Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report
Summary:We evaluated the effect of alefacept (Amevive), a novel dimeric fusion protein, in steroid resistant/dependent acute… 
Highly Cited
2003
Highly Cited
2003
Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.
This international, double-blind study examined the effects of alefacept on circulating lymphocytes in 507 patients with chronic… 
Highly Cited
2003
Highly Cited
2003
Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis
Background There is a current lack of safe and effective psoriasis therapies that provide patients with lasting remissions after… 
2003
2003
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy
Background Psoriasis is a chronic, relapsing skin disease that may require multiple treatment courses. Alefacept targets the… 
2002
2002
Pharmacokinetics, Biologic Activity, and Tolerability of Alefacept by Intravenous and Intramuscular Administration
Alefacept, human LFA-3/IgG1 fusion protein, is currently under clinical development for the treatment of chronic plaque psoriasis… 
Highly Cited
1996
Highly Cited
1996
Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival.
The interaction of T cell costimulatory molecules with their ligands is required for optimal T cell activation. Interference with… 
Highly Cited
1994
Highly Cited
1994
Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice.
Soluble ligands specific for cell surface molecules involved in APC-T cell interactions can signal cells and modulate immune… 
Highly Cited
1993
Highly Cited
1993
Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses
Accessory cell surface molecules, such as T cell antigen CD2 and its ligand lymphocyte function-associated antigen 3 (LFA-3; CD58… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)